Bioventus Inc (BVS)
Healthcare
Medical Devices
13.20 $
-0.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Bioventus Inc (BVS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 49.2% of the shares are freely tradable; institutional investors hold 78.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
78.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
11.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
49.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
68Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Essex Woodlands Health Ventures | 19.22 | 13,021,324 | +0.0 | 03/31/2026 |
| Juniper Investment Co, LLC | 10.24 | 6,939,357 | +0.0 | 03/31/2026 |
| Nantahala Capital Management, LLC | 9.04 | 6,122,403 | +1.2 | 03/31/2026 |
| BlackRock Inc | 4.63 | 3,133,541 | +0.3 | 03/31/2026 |
| Vanguard Group Inc | 4.41 | 2,984,927 | +2.1 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.53 | 1,714,707 | +0.0 | 03/31/2026 |
| Royce & Associates, LP | 2.28 | 1,541,282 | +23.2 | 03/31/2026 |
| Geode Capital Management, LLC | 1.72 | 1,168,247 | +4.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.72 | 1,163,677 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 1.66 | 1,126,763 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.